SEC Form 4 · accession 0001171000-15-000110
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Gearing
Officer — Chief Scientific Officer
Period of report
Nov 23, 2015
Accepted (ET)
Nov 24, 2015 · 3:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 23, 2015 | M | 5,600 | $0.125 | A | 279,330 | I | By Gearing Family Pty Ltd <Gearing Family A/C> |
| Ordinary Shares | holding | — | — | — | 5,600 | D | ||
| Ordinary SharesF1 | holding | — | — | — | 83,664 | I | By DJGearing Pty Ltd <Gearing Family Superannuation Fund A/C> |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase sharesF1,F2 | $0.125 | Nov 23, 2015 | M | 5,600 | D | — | Jul 1, 2019 | Ordinary Shares | 5,600 | 7,466 | I |
Explanation of responses
- F1The reporting person and his spouse have shared voting and dispositive power with respect to these reported securities.
- F25,600 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 3,733 options will vest and be exercisable on each of 7/1/16 and 1/1/17.